Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group

Sotirios G Papageorgiou; Ioannis Kotsianidis; Christos K Kontos; Argyris Symeonidis; Athanasios Galanopoulos; Eleftheria Hatzimichael; Elias Poulakidas; Panagiotis Diamantopoulos; Theodoros P Vassilakopoulos; Panagiotis Zikos; Helen Papadaki; Eleni Bouronikou; Panayiotis Panayiotidis; Nora-Athina Viniou; Vasiliki Pappa

doi:10.1016/j.leukres.2018.07.004

Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group

Leuk Res. 2018 Aug:71:55-59. doi: 10.1016/j.leukres.2018.07.004. Epub 2018 Jul 7.

Authors

Sotirios G Papageorgiou¹, Ioannis Kotsianidis², Christos K Kontos³, Argyris Symeonidis⁴, Athanasios Galanopoulos⁵, Eleftheria Hatzimichael⁶, Elias Poulakidas⁷, Panagiotis Diamantopoulos⁸, Theodoros P Vassilakopoulos⁹, Panagiotis Zikos¹⁰, Helen Papadaki¹¹, Eleni Bouronikou¹², Panayiotis Panayiotidis¹³, Nora-Athina Viniou¹⁴, Vasiliki Pappa¹⁵

Affiliations

¹ Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462, Athens, Greece. Electronic address: sotirispapageorgiou@hotmail.com.
² Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece; The Hellenic (Greek) MDS Study Group, Greece.
³ Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701, Athens, Greece.
⁴ The Hellenic (Greek) MDS Study Group, Greece; General University Hospital of Patras, Rio Patron, 26500, Patras, Greece.
⁵ The Hellenic (Greek) MDS Study Group, Greece; General Hospital of Athens "G. Gennimatas", Mesogeion 154, 11527, Athens, Greece.
⁶ University Hospital of Ioannina, 45100, Ioannina, Greece.
⁷ "401" Army General Hospital of Athens, Mesogeion and Kanellopoulou 1, 11525, Athens, Greece.
⁸ 1st Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
⁹ Department of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
¹⁰ General Hospital of Patras "Agios Andreas", Tsertidou 1, 26335, Patras, Greece.
¹¹ University General Hospital of Heraklion, Voutes, 71110, Heraklion, Greece.
¹² University General Hospital of Larissa, Mezourlo, 41110, Larissa, Greece.
¹³ 1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
¹⁴ The Hellenic (Greek) MDS Study Group, Greece; 1st Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
¹⁵ Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462, Athens, Greece; The Hellenic (Greek) MDS Study Group, Greece.

PMID: 30007218
DOI: 10.1016/j.leukres.2018.07.004

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / administration & dosage*
Azacitidine / administration & dosage*
Body Mass Index
Dose-Response Relationship, Drug
Female
Greece
Humans
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy*
Retrospective Studies
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Azacitidine